NuVision
Nottingham
About NuVision
NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at the University of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $14.2M
- Last round: Series Unknown (Feb 2026)
- Website: nu-vision.co.uk
- Phone: 44 (0) 7879610023
Industries & Categories
Biotechnology, Quality Assurance, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/nuvision-131132 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.